BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of Allocetra TM (formerly referred to as off-the-shelf Allocetra TM ) in COVID-19 patients has commenced. “While work investigating the exact pathophysiology of COVID-19 is ongoing, recent publications have described the complications related to the virally induced COVID-19 di

ClearPoint Neuro, Inc. announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close.

CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium channels for the treatment of acute and severe inflammatory diseases, announced that the Independent Safety Review Committee recommended that its open-label Phase 2 study evaluating the safety, efficacy and pharmacokinetic profile of CM4620-IE in patients with severe COVID-19 pneumonia continue as planned.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is eng

West Pharmaceutical Services, Inc. announced it will participate in the Bank of America Securities 2020 Healthcare Conference on Thursday, May 14, 2020, as well as the Jeffries Virtual Healthcare Conference 2020 on Tuesday, June 2, 2020.

Targeted short-form messaging, combined with digital continuing medical education to clinicians, was found to significantly reduce the inappropriate prescribing of antibiotics, according to the results of a new study, conducted by Medscape in collaboration with the U.S. Food and Drug Administration, and published in Pharmacy Practice.

Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close.

End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected to be announced in the second quarter

Kidney care company continues to help teammates by providing relief reimbursement, back-up child care and free counseling

Option Care Health, Inc., the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2020.